Evidence & regulatory context
- Mechanism
- Coagulation factor X inhibitor
- Target
- Coagulation factor X
- Injury models
- Other
- Reported indication
- Oral factor Xa inhibitor anticoagulant: prevention/treatment of VTE (DVT/PE), stroke prevention in non-valvular AF, CAD/PAD; FDA-approved 2011 (Xarelto)
- First approval
- 2008
- Development stage
- Approved anticoagulant for thromboembolic disease; acute-injury use investigational
- ChEMBL max phase
- 4 / 4 (development scale, not regulatory approval)
- Synonyms
- BAY 59-7939; BAY-59-7939; JNJ-39039039; JNJ39039039; Rivaroxaban; Rivaroxaban accord; Rivaroxaban viatris (previously rivaroxaban mylan); Xarelto
- Note
- Not recorded
Clinical trials 10
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Safety and Efficacy of Century Clot-Guided Prophylactic Rivaroxaban Therapy for Post ST-Segment Elevation Myocardial Infarction Complicating Left Ventricular Thrombus Compared With Conventional Antiplatelet Therapy
STEMI - ST Elevation Myocardial Infarction
Enrolment: 374 · Results not recorded
Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism: a Multicenter Randomized Placebo-controlled Non-inferiority Trial
Pulmonary Embolism · Venous Thromboembolism
Enrolment: 276 · Results not recorded
The Efficacy and Safety of Prophylactic Anticoagulation for Catheter-related Thrombosis in Patients With Cancer and Implantable Venous Access Ports: a Prospective Multi-center Randomized Controlled Trial.
Venous Thrombosis Due to Central Venous Access Device (Disorder) · Prophylactic Anticoagulation
Enrolment: 1640 · Results not recorded
An Efficacy and Safety Study of New Oral Anticoagulants and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters: A Prospective Randomized Controlled Trial
Venous Thromboembolism
Enrolment: 200 · Results not recorded
Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer: a Randomized, Double Blind, Placebo-controlled Study.
Prevention of Venous Thromboembolism
Enrolment: 582 · Results not recorded
Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome
Behcet Syndrome
Enrolment: 134 · Results not recorded
Rivaroxaban in Type 2 Myocardial Infarctions: A Feasibility, Placebo-controlled, Double-blinded, Randomized Controlled Trial
Type II Myocardial Infarction
Enrolment: 8 · Results not recorded
Randomized Trial to Test the Effect of Rivaroxaban or Apixaban on Menstrual Blood Loss in Women
Venous Thromboembolism · Menstruation
Enrolment: 19 · Results not recorded
Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics.
Healthy
Enrolment: 12 · Results not recorded
Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)
Heart Failure
Enrolment: 552 · Results not recorded
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatOtherSprague-DawleyMaleIntravenous infusion, and oral dosing at the highest dose0.3, 1 or 3 mg/kg intravenously; also 3 mg/kg orallyAdministered before electrolytic carotid injury, with time to occlusion monitor…
Model: Electrolytic injury of the carotid artery in anaesthetised rats, producing thrombotic vessel occlusion
Rivaroxaban at 1 and 3 mg/kg prevented occlusion in all vessels across the 30 min observation window (median occlusion time greater than 30 min), exceeding enoxaparin 10 mg/kg (median 21.6 min), while 0.3 mg/kg did not prolong occlusion time versus vehicle. Oral dosing at 3 mg/kg was also effective…
Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.
